Joshua Adams, MD
Family Medicine · Boise, IDNPI 1568789980
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Amgen at 25.0% of the total. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$773
- Lilly USA, LLC$737
- GSK$722
- Pfizer$689
- AbbVie$642
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,243100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 48 | $2,067 |
| AstraZeneca | 25 | $773 |
| Lilly USA, LLC | 48 | $737 |
| GSK | 31 | $722 |
| Pfizer | 46 | $689 |
| AbbVie(2 entities) | 39 | $642 |
| Abbott | 9 | $405 |
| Novo Nordisk | 25 | $372 |
| Novartis | 10 | $210 |
| Dexcom, Inc. | 7 | $186 |
| Boehringer Ingelheim | 8 | $161 |
| Bayer | 8 | $158 |
| Exact Sciences | 7 | $151 |
| Merck | 8 | $135 |
| Edwards Lifesciences | 2 | $117 |
| Gilead | 1 | $104 |
| Johnson & Johnson | 5 | $89 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Boston Scientific | 1 | $52 |
| Quidel Corporation | 1 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $26 |
| Verona Pharma, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $17 |
| Exeltis, USA Inc. | 1 | $14 |
| Sonex Health, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Corium, LLC | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$827
- FreeStyle Libre$142
- FreeStyle Libre 2$124
- BREZTRI$122
- FARXIGA$122
- JARDIANCE$114
- SHINGRIX$109
- ZEPBOUND$105
- Yescarta$104
How this compares
$8,255 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 224 | $266,934 |
| EliquisApixaban | 110 | $121,705 |
| OzempicSemaglutide | 100 | $97,240 |
| JardianceEmpagliflozin | 67 | $89,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $73,393 |
| TrulicityDulaglutide | 54 | $61,855 |
| FarxigaDapagliflozin Propanediol | 34 | $53,790 |
| Repatha SureclickEvolocumab | 33 | $26,781 |
| XareltoRivaroxaban | 15 | $19,925 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $16,137 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $15,293 |
| Spiriva HandihalerTiotropium Bromide | 16 | $10,212 |
| Repatha SyringeEvolocumab | 14 | $7,525 |
| BelsomraSuvorexant | 13 | $5,931 |
| Atorvastatin Calcium | 565 | $5,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $737 | $328,789278 claims |
| PfizerEliquis | $689 | $121,705110 claims |
| Novo NordiskOzempic | $372 | $97,240100 claims |
| Boehringer IngelheimJardiance | $161 | $89,84567 claims |
| GSKTrelegy Ellipta | $722 | $73,39376 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $773 | $69,92754 claims |
| Johnson & JohnsonXarelto | $89 | $19,92515 claims |
| MerckBelsomra | $135 | $5,93113 claims |
| AbbVieSynthroid | $642 | $2,89125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.
Other family medicine in Boise
- Phyllis YouBoise$88K
- Kara CadwalladerBoise$24K
- Cyrus VaniaBoise$9K
- Nicole StiversBoise$7K
- Ammon RobertsBoise$7K
- Ryan MooreBoise$5K
- Mary NagleBoise$4K
- Kenneth CongerSandpoint$266K
- David ButukMeridian$206K
- Anne BroadwayIdaho Falls$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.